» Articles » PMID: 32308997

Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen

Overview
Publisher Wiley
Date 2020 Apr 21
PMID 32308997
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Triple negative breast cancer (TNBC) is associated with aggressive tumour phenotype and early tumour relapse following diagnosis. Generally, clinicopathological features such as tumour size, patient's age at diagnosis, tumour histology subtypes, grade and stage, involvement of lymph nodes, and menopausal status are commonly used for predicting disease progression, prospects of recurrence, and treatment response. Prognostic value of clinicopathological features on Malaysian TNBC patients is limited. Thus, this study is aimed at investigating the association of clinicopathological features on disease-free survival (DFS) and overall survival (OS) of Malaysian TNBC patients undergoing TAC chemotherapy. Seventy-six (76) immunohistochemistry-confirmed TNBC patients were recruited. The clinicopathological features of TNBC patients were collected and recorded. Kaplan-Meier and log-rank followed by a Cox proportional hazard regression model were performed to evaluate the TNBC patients' survival. Out of 76 TNBC patients, 25 were chemoresistant and 51 were chemoresponders to the TAC chemotherapy regimen. The overall 5-year cumulative DFS and OS of TNBC patients were 63.5% and 76.3%, respectively. Multivariate Cox analysis demonstrated that medullary and metaplastic histology subtypes and positive axillary lymph node metastasis were significant prognostic factors associated with relapse with adjusted HR: 5.76, 95% CI: 2.35, 14.08 and adjusted HR: 3.55, 95% CI: 1.44, 8.74, respectively. Moreover, TNBC patients with medullary and metaplastic histology subtypes and positive axillary lymph node metastases had a higher risk to death than patients who had infiltrating ductal carcinoma and negative axillary lymph node metastasis (adjusted HR: 8.30, 95% CI: 2.38, 28.96 and adjusted HR: 6.12, 95% CI: 1.32, 28.42, respectively). Our results demonstrate the potential use of medullary and metaplastic histology subtype and positive axillary lymph node metastasis as a potential biomarker in predicting relapse and survival of the TNBC patients. This warrants further studies on intensification of chemotherapy and also identification and development of targeted therapy to reduce relapses and improve survival of TNBC patients.

Citing Articles

Clinical significance of regulatory T cells and T lymphocyte subsets in peripheral blood in neoadjuvant chemotherapy for breast cancer.

Mao X, Chen S, Shen S, Liu K Am J Cancer Res. 2023; 13(7):3091-3099.

PMID: 37559980 PMC: 10408470.


Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 & SATB1 in HER-2-Positive breast cancer patients.

Chen Z, Sang M, Geng C, Hao W, Jia H Pak J Med Sci. 2022; 38(3Part-I):553-559.

PMID: 35480523 PMC: 9002432. DOI: 10.12669/pjms.38.3.5199.


Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer.

Ding J, Xiao Y, Zhao S, Xu Y, Xiao Y, Shao Z Mol Ther Oncolytics. 2022; 24:624-635.

PMID: 35284626 PMC: 8898759. DOI: 10.1016/j.omto.2022.02.003.


Regulation of Cellular and Cancer Stem Cell-Related Putative Gene Expression of Parental and CD44CD24 Sorted MDA-MB-231 Cells by Cisplatin.

Koh M, Ho W, Yeap S, Ali N, Boo L, Alitheen N Pharmaceuticals (Basel). 2021; 14(5).

PMID: 33919109 PMC: 8143088. DOI: 10.3390/ph14050391.

References
1.
Sun W, Li C, Liu M, Liu W, Yang C, Cai L . Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. Oncol Lett. 2016; 11(3):2320-2326. PMC: 4774624. DOI: 10.3892/ol.2016.4176. View

2.
Martin M, Segui M, Anton A, Ruiz A, Ramos M, Adrover E . Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010; 363(23):2200-10. DOI: 10.1056/NEJMoa0910320. View

3.
Bauer K, Brown M, Cress R, Parise C, Caggiano V . Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109(9):1721-8. DOI: 10.1002/cncr.22618. View

4.
Liao H, Zhang W, Sun J, Li F, He Z, Wu S . The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer. J Cancer. 2018; 9(2):296-303. PMC: 5771337. DOI: 10.7150/jca.22280. View

5.
Dawson S, Provenzano E, Caldas C . Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009; 45 Suppl 1:27-40. DOI: 10.1016/S0959-8049(09)70013-9. View